Der Hautarzt

, 62:423

Therapie des inoperabel metastasierten Melanoms

Leitthema

Zusammenfassung

In der Vergangenheit war die Therapie des fortgeschrittenen Melanoms im Stadium der Fernmetastasierung von einem oft nur limitierten Erfolg gekennzeichnet. Die in den letzten Jahren gewonnenen Erkenntnisse zur Pathogenese und Immunologie des Melanoms ermöglichten die Entwicklung neuer vielversprechender Therapieansätze für bestimmte Gruppen von Melanompatienten. In der vorliegenden Arbeit werden neben diesen molekular gerichteten und immunmodulierenden Therapien auch bereits länger etablierte Therapien wie die Strahlen- oder Chemotherapie diskutiert.

Schlüsselwörter

Fernmetastasiertes Melanom Strahlentherapie Chemotherapie Immuntherapie Targeted Therapie 

Treatment of advanced metastatic melanoma

Abstract

In the past therapy of advanced melanoma with distant metastases was characterized by limited success. In recent years the increased understanding of the pathogenesis of melanoma as well as tumor immunology, however, has allowed the development of new promising therapeutic options for certain subgroups of melanoma patients. In the present review these molecular-targeted and immune-modulating therapies, as well as already established therapies such as radiation or chemotherapy, will be discussed.

Keywords

Advanced metastatic melanoma Radiation therapy Chemotherapy Immunotherapy Targeted therapy 

Literatur

  1. 1.
    Balch CM, Gershenwald JE et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206PubMedCrossRefGoogle Scholar
  2. 2.
    Bedikian AY, Johnson MM et al (2008) Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. J Immunotoxicol 5(2):201–207PubMedCrossRefGoogle Scholar
  3. 3.
    Brown PD, Brown C A et al (2002) Stereotactic radiosurgery for patients with radioresistant brain metastases. Neurosurgery 51(3):656–665PubMedGoogle Scholar
  4. 4.
    Buchsbaum JC, Suh JH et al (2002) Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer 94(8):2265–2272PubMedCrossRefGoogle Scholar
  5. 5.
    Carter SK, Friedman MA (1972) 5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388) – a new antitumor agent with activity against malignant melanoma. Eur J Cancer 8(1):85–92PubMedGoogle Scholar
  6. 6.
    Chang EL, Wefel JS et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10(11):1037–1044PubMedCrossRefGoogle Scholar
  7. 7.
    Curtin JA, Busam K et al (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340–4346PubMedCrossRefGoogle Scholar
  8. 8.
    Eigentler TK, Caroli UM et al (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4(12):748–759PubMedCrossRefGoogle Scholar
  9. 9.
    Flaherty KT, Puzanov I et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9):809–819PubMedCrossRefGoogle Scholar
  10. 10.
    Gerstner ER, Fine RL (2007) Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 25(16):2306–2312PubMedCrossRefGoogle Scholar
  11. 11.
    Hodi FS, Friedlander P et al (2008) Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26(12):2046–2051PubMedCrossRefGoogle Scholar
  12. 12.
    Hodi FS, O’Day SJ et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723PubMedCrossRefGoogle Scholar
  13. 13.
    Kaehler KC, Piel S et al (2010) Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 37(5):485–498PubMedCrossRefGoogle Scholar
  14. 14.
    Keilholz U, Punt CJ et al (2005) Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 23(27):6747–6755PubMedCrossRefGoogle Scholar
  15. 15.
    Ko JM, Fisher DE (2010) A new era: melanoma genetics and therapeutics. J Pathol 223(2):241–250PubMedGoogle Scholar
  16. 16.
    Kortmann RD, Hoffmann W et al (1995) Radiotherapie bei Tumorschmerz. Onkologe 1:327–334Google Scholar
  17. 17.
    Poulikakos PI, Zhang C et al (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464(7287):427–430PubMedCrossRefGoogle Scholar
  18. 18.
    Rades D, Freundt K et al (2010) Dose escalation for metastatic spinal cord compression in patients with relatively radioresistant tumors. Int J Radiat Oncol Biol Phys [Epub ahead of print]Google Scholar
  19. 19.
    Schadendorf D, Ugurel S et al (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17(4):563–570PubMedCrossRefGoogle Scholar
  20. 20.
    Schrama D, Reisfeld RA et al (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5(2):147–159PubMedCrossRefGoogle Scholar
  21. 21.
    Solit DB, Rosen N (2011) Resistance to BRAF inhibition in melanomas. N Engl J Med 364(8):772–774PubMedCrossRefGoogle Scholar
  22. 22.
    Terheyden P, Houben R et al (2010) Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene. J Invest Dermatol 130(1):314–316PubMedCrossRefGoogle Scholar
  23. 23.
    Testori A, Rutkowski P et al (2009) Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol 20 Suppl 6(6):vi22–vi29Google Scholar
  24. 24.
    Ugurel S, Hildenbrand R et al (2005) Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92(8): 1398–1405PubMedCrossRefGoogle Scholar
  25. 25.
    Ugurel S, Schadendorf D et al (2006) In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res 12(18):5454–5463PubMedCrossRefGoogle Scholar
  26. 26.
    Ugurel S, Utikal J et al (2009) Tumor biomarkers in melanoma. Cancer Control 16(3):219–224PubMedGoogle Scholar
  27. 27.
    Weide B, Eigentler TK et al (2010) Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunol Immunother [Epub ahead of print]Google Scholar
  28. 28.
    Wyman K, Atkins MB et al (2006) Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106(9): 2005–2011PubMedCrossRefGoogle Scholar
  29. 29.
    Yu AL, Gilman AL et al (1324) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363(14):1324–1334CrossRefGoogle Scholar
  30. 30.
    Garbe C et al (2008) ADO Kurzleitlinie – malignes Melanom der HautGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Allgemeine DermatologieMedizinische Universität GrazGrazÖsterreich

Personalised recommendations